{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:27Z","timestamp":1761896547421},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/leu.2017.124","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T06:41:19Z","timestamp":1493102479000},"page":"1816-1819","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma"],"prefix":"10.1038","volume":"31","author":[{"given":"S","family":"Knop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L-O","family":"M\u00fcgge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Reichle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"R\u00f6sler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Bassermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kunitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ringhoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Biersack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Schreder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Liebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Held","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R C","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Deutsche Studiengruppe Multiples Myelom (DSMM)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"BFleu2017124_CR1","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196\u20131198.","journal-title":"Blood"},{"key":"BFleu2017124_CR2","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","volume":"29","author":"B Bjorkstrand","year":"2011","unstructured":"Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016\u20133022.","journal-title":"J Clin Oncol"},{"key":"BFleu2017124_CR3","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","volume":"121","author":"G Gahrton","year":"2013","unstructured":"Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055\u20135063.","journal-title":"Blood"},{"key":"BFleu2017124_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110\u20131120.","journal-title":"N Engl J Med"},{"key":"BFleu2017124_CR5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: 1195\u20131203.","journal-title":"Lancet Oncol"},{"key":"BFleu2017124_CR6","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","volume":"107","author":"F Garban","year":"2006","unstructured":"Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474\u20133480.","journal-title":"Blood"},{"key":"BFleu2017124_CR7","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","volume":"112","author":"L Rosinol","year":"2008","unstructured":"Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591\u20133593.","journal-title":"Blood"},{"key":"BFleu2017124_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/bmt.2012.173","volume":"48","author":"KE Armeson","year":"2013","unstructured":"Armeson KE, Hill EG, Costa LJ . Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013; 48: 562\u2013567.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2017124_CR9","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Multiple myeloma. Version 3. 2016. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf (accessed 24 May 2016)."},{"key":"BFleu2017124_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301\u2013305.","journal-title":"Science"},{"key":"BFleu2017124_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014; 343: 305\u2013309.","journal-title":"Science"},{"key":"BFleu2017124_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nm.4128","volume":"22","author":"R Eichner","year":"2016","unstructured":"Eichner R, Heider M, Fernandez-Saiz V, van Bebber F, Garz AK, Lemeer S et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 2016; 22: 735\u2013743.","journal-title":"Nat Med"},{"key":"BFleu2017124_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/leu.2016.384","volume":"31","author":"J Kr\u00f6nke","year":"2017","unstructured":"Kr\u00f6nke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia 2017; 31:1363\u20131367.","journal-title":"Leukemia"},{"key":"BFleu2017124_CR14","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434\u20132441.","journal-title":"J Clin Oncol"},{"key":"BFleu2017124_CR15","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","volume":"113","author":"S Knop","year":"2009","unstructured":"Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113: 4137\u20134143.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2017124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017124","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:28:29Z","timestamp":1648747709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFleu2017124"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.124","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2017,4,25]]},"assertion":[{"value":"25 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stock ownership: WR, Amgen, Immunomedics. Honoraria: SK, Celgene Germany, Amgen Germany, BMS Germany, ONYX Inc., Janssen Germany; ME, Celgene, Janssen, MSD, Amgen; L-OM, Celgene, Janssen-Cilag, Novartis; FB, Celgene; MR, Celgene; AG, Novartis, Celgene, Janssen; MS, Novartis; HE, Janssen, Amgen, Novartis, Celgene; RCB, Amgen, Novartis, GeoMab. Consultant or advisory role: SK, Celgene Germany, Amgen Germany, Celgene Inc.; CL, Celgene, Janssen, Amgen, Novartis, Takeda, BMS; <i>ME<\/i>, Celgene, Janssen, MSD, Amgen; WR, Janssen, MSD; FB, Celgene; BH, Amgen; CR, Amgen, BMS, Celgene, Janssen, Roche, Takeda; HO, MSD, Gilead, AstraZeneca, Teva; <i>AG<\/i>, Novartis, Takeda; HB, BMS, Roche, Pfizer, MSD, Sanofi; HE, Janssen, Celgene, Amgen; RCB, Amgen, Novartis, GeoMab. Speakers\u2019 bureau: CR, Amgen, BMS, Celgene, Janssen, Roche, Takeda; HO, MSD, AstraZeneca, Novartis, Teva; HE, Janssen, Celgene, Novartis. Research funding: L-OM, Celgene; FB, Celgene; CR, Bayer; HO, MSD, Genzyme, Cereus; HE, Amgen, Celgene, Janssen. Patents, royalties, other intellectual property: RCB, Amgen. Travel, accommodation, expenses: CL, Celgene, Takeda, BMS; ME, Celgene, Janssen, MSD, Amgen; L-OM, Novartis, Celgene; WR, medac, Janssen, MSD; <i>FB<\/i>, Celgene, BMS; <i>BH<\/i>, Teva, Amgen, Novartis, Neovi; CR, Amgen, Celgene, Janssen, Gilead; HO, MSD, Gilead, AstraZeneca; MR, medac; HB, Jazz, Eusapharma, Sanofi, Amgen; MS, Celgene; RCB, Amgen, Novartis, GeoMab. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}